Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.
|Number of pages||9|
|Journal||Journal of the National Cancer Institute|
|Publication status||Published - 2009|